Skip to Main Content

Author Details

Amalio Telenti
Vir Biotechnology Inc.
1977
412
93
PMIDPaper TitleJournal TitlePublished Year
36629998Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.Infect Dis Ther2023
37745933A framework for future national pediatric pandemic respiratory disease severity triage: The HHS pediatric COVID-19 data challenge.J Clin Transl Sci2023
37927427Epidemiology and determinants of reemerging bacterial sexually transmitted infections (STIs) and emerging STIs in Europe.Lancet Reg Health Eur2023
37613467How a Potent Anti-neuraminidase Monoclonal Antibody Navigates Recent Immune-evasive Influenza Strains: A Structural Study by Single-particle CryoEM.Microsc Microanal2023
37407829Author Correction: A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.Nature2023
37459920Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.J Hepatol2023
37258672A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.Nature2023
36629998Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.Infect Dis Ther2023
37745933A framework for future national pediatric pandemic respiratory disease severity triage: The HHS pediatric COVID-19 data challenge.J Clin Transl Sci2023
37613467How a Potent Anti-neuraminidase Monoclonal Antibody Navigates Recent Immune-evasive Influenza Strains: A Structural Study by Single-particle CryoEM.Microsc Microanal2023
37927427Epidemiology and determinants of reemerging bacterial sexually transmitted infections (STIs) and emerging STIs in Europe.Lancet Reg Health Eur2023
37459920Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.J Hepatol2023
37258672A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.Nature2023
37407829Author Correction: A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.Nature2023
34709663MP-NeRF: A massively parallel method for accelerating protein structure reconstruction from internal coordinates.J Comput Chem2022
35700730Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein.Cell2022
35444005The Evolution and Biology of SARS-CoV-2 Variants.Cold Spring Harb Perspect Med2022
35821254Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.Cell Mol Immunol2022
36203553Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape.bioRxiv2022
35977462Antibody therapy reverses biological signatures of COVID-19 progression.Cell Rep Med2022
36523407Severe acute infection and chronic pulmonary disease are risk factors for developing post-COVID-19 conditions.medRxiv2022
35016195Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature2022
35014856Predicting the mutational drivers of future SARS-CoV-2 variants of concern.Sci Transl Med2022
34709663MP-NeRF: A massively parallel method for accelerating protein structure reconstruction from internal coordinates.J Comput Chem2022
35444005The Evolution and Biology of SARS-CoV-2 Variants.Cold Spring Harb Perspect Med2022
35700730Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein.Cell2022
35821254Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.Cell Mol Immunol2022
36523407Severe acute infection and chronic pulmonary disease are risk factors for developing post-COVID-19 conditions.medRxiv2022
36203553Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape.bioRxiv2022
35977462Antibody therapy reverses biological signatures of COVID-19 progression.Cell Rep Med2022
35016195Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.Nature2022
35014856Predicting the mutational drivers of future SARS-CoV-2 variants of concern.Sci Transl Med2022
33469588N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.bioRxiv2021
33489013Dissemination of <i>Mycobacterium tuberculosis</i> is associated to a <i>SIGLEC1</i> null variant that limits antigen exchange via trafficking extracellular vesicles.J Extracell Vesicles2021
34237771After the pandemic: perspectives on the future trajectory of COVID-19.Nature2021
33851169Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody.bioRxiv2021
33851154Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.bioRxiv2021
34280951Broad sarbecovirus neutralization by a human monoclonal antibody.Nature2021
33469588N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.bioRxiv2021
33948580Analysis of Brugada syndrome loci reveals that fine-mapping clustered GWAS hits enhances the annotation of disease-relevant variants.Cell Rep Med2021
33621484Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.Cell2021
34210893SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.Science2021
34261126SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.Nature2021
34031243Transfer transcriptomic signatures for infectious diseases.Proc Natl Acad Sci U S A2021
33821281SARS-CoV-2 immune evasion by variant B.1.427/B.1.429.bioRxiv2021
33761326N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.Cell2021
34344823Broad betacoronavirus neutralization by a stem helix-specific human antibody.Science2021
34464958Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies.Nature2021
34782760SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.Cell Mol Immunol2021
34931194Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.bioRxiv2021
  • 1 - 50 of 824

Recommended Authors

Shuntai Zhou
University of North Carolina at Chapel Hill
Career Start Year 2010
Number of shared co-authors 2
Will Dampier
Drexel University College of Medicine
Career Start Year 2007
Number of shared co-authors 1
Vivek Naranbhai
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2006
Number of shared co-authors 14
Fabio Zanini
Stanford University
Career Start Year 2006
Number of shared co-authors 0
Timo Wolf
Goethe University Frankfurt, University Hospital
Career Start Year 2003
Number of shared co-authors 3
Timothy J Henrich
University of California san francisco
Career Start Year 2002
Number of shared co-authors 10
Satish K Pillai
Vitalant Research Institute, USA University of California san francisco
Career Start Year 2001
Number of shared co-authors 6
Davey M Smith
University of California San Diego
Career Start Year 2001
Number of shared co-authors 13
Pardis C Sabeti
Harvard University
Career Start Year 1997
Number of shared co-authors 29
Viviana Simon
Icahn School of Medicine at Mount Sinai
Career Start Year 1997
Number of shared co-authors 6
Sharon R Lewin
The University of Melbourne at the Peter Doherty Institute for Infection and Immunity
Career Start Year 1993
Number of shared co-authors 10
Wei Shao
Inc., Frederick National Laboratory for Cancer Research
Career Start Year 1993
Number of shared co-authors 4
Huyen Nguyen
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
Career Start Year 1990
Number of shared co-authors 3
Carl J Fichtenbaum
University of Cincinnati
Career Start Year 1988
Number of shared co-authors 6
Jason Flamm
Sacramento Medical Center, Kaiser Permanente Northern California
Career Start Year 1988
Number of shared co-authors 2
Andy I M Hoepelman
University Medical Center Utrecht
Career Start Year 1988
Number of shared co-authors 6
Jonathan M Woo
University of California san francisco
Career Start Year 1988
Number of shared co-authors 1
Pablo Tebas
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1988
Number of shared co-authors 13
Susan Swindells
University of Nebraska Medical Center
Career Start Year 1987
Number of shared co-authors 4
Ian Frank
IF School of Medicine, University of Pennsylvania
Career Start Year 1987
Number of shared co-authors 11
Virginia L Kan
VA Medical Center
Career Start Year 1986
Number of shared co-authors 2
Richard T Davey
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1985
Number of shared co-authors 8
Ann C Collier
University of Washington
Career Start Year 1984
Number of shared co-authors 13
Stephen Raffanti
Vanderbilt University Medical Center
Career Start Year 1983
Number of shared co-authors 4
Barbara Gripshover
Case Western Reserve University
Career Start Year 1981
Number of shared co-authors 2
Michael S Saag
University of Alabama at Birmingham
Career Start Year 1980
Number of shared co-authors 14
Dushyantha Jayaweera
University of Miami, Miller School of Medicine
Career Start Year 1977
Number of shared co-authors 2
Ronald Swanstrom
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 1972
Number of shared co-authors 6
Richard A Kaslow
University of Alabama at Birmingham
Career Start Year 1972
Number of shared co-authors 8
Luis J Montaner
Wistar Institute
Career Start Year 1958
Number of shared co-authors 7

Collaborators

Jacques Fellay
Ecole Polytechnique Federale de Lausanne
Co-authored papers 43
Matthias Cavassini
Lausanne University Hospital, University of Lausanne
Co-authored papers 32
Paul J McLaren
Co-authored papers 24
J C Venter
The J. Craig Venter Institute
Co-authored papers 21
David B Goldstein
Institute for Genomic Medicine, Columbia University Irving Medical Center
Co-authored papers 18
Mary Carrington
Frederick National Laboratory for Cancer Research, National Cancer Institute
Co-authored papers 16
David Veesler
Co-authored papers 16
Alexandra C Walls
Co-authored papers 15
Bonaventura Clotet
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 13
Nadine Czudnochowski
University of California san francisco
Co-authored papers 12
Rubin Lubomirov
Clinical Development
Co-authored papers 10
Ewen F Kirkness
J. Craig Venter Institute
Co-authored papers 10
Laurent Kaiser
Geneva University Hospital
Co-authored papers 10
Nuria Izquierdo-Useros
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 9
Pejman Mohammadi
Co-authored papers 8
Steven M Wolinsky
Northwestern University Feinberg School of Medicine
Co-authored papers 8
Jacques S Beckmann
University of Lausanne
Co-authored papers 8
Michael C Maher
Vir Biotechnology Inc.
Co-authored papers 8
Roberto Spreafico
Co-authored papers 7
Stephen J O'Brien
Co-authored papers 7
Ying Qi
Co-authored papers 7
Bruce D Walker
Ragon Institute of Mass General
Co-authored papers 7
Kevin V Shianna
Illumina Inc. 5200 Illumina Way
Co-authored papers 7
Dongliang Ge
Department of Pharmacy, Liyang People's Hospital
Co-authored papers 6
Steven G Deeks
University of California san francisco
Co-authored papers 6
Daniel R Kuritzkes
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 6
Michael S Diamond
Washington University School of Medicine
Co-authored papers 5
Xiaoqian Jiang
Carnegie Mellon University, The University of Texas Health Science Center at Houston, University of California San Diego
Co-authored papers 5
Vincent Mooser
McGill University
Co-authored papers 5
Yaron Turpaz
Pte. Ltd.
Co-authored papers 5
Release 1.2